Manages vasospastic angina confirmed. ANDA 72781, held by Acella. Nifedipine.
As of Nov 16, 2026, ANDA 72781 (Nifedipine), held by Acella, was first approved by FDA on Jul 30, 1993, with 3 approved supplements and 0 published complete response letters.
INDICATIONS AND USAGE I. Vasospastic Angina Nifedipine is indicated for the management of vasospastic angina confirmed by any of the following criteria: 1) classical pattern of angina at rest accompanied by ST segment elevation, 2) angina or coronary artery spasm provoked by ergonovine, or 3) angiographically demonstrated coronary artery spasm. In those patients who have had angiography, the presence of significant fixed obstructive disease is not incompatible with the diagnosis of vasospastic angina, provided that the above criteria are satisfied.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Jul 30, 1993 | Original application | Approved | None posted |
| Product | Active ingredient | Marketing |
|---|---|---|
| Nifedipine10MG · capsule;oral | Nifedipine | Rx |
| Sep 2, 2009 | Supplement 11Labeling | Approved | None posted |
| Dec 9, 1994 | Supplement 6Manufacturing | Approved | None posted |
| Dec 9, 1994 | Supplement 7Labeling | Approved | None posted |
| Jul 30, 1993 | Original application | Approved | None posted |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters